← Back
Data updated: Sep 20, 2026
ZEVRA DENMARK
Pharma Pharmaceuticals
ZEVRA DENMARK is a pharmaceutical company with 1 FDA-approved products.
2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2024) 1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Priority Review 1 Fast Track
See 1 novel approval →
2024 MIPLYFFA (ARIMOCLOMOL CITRATE) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
ZEVRA DENMARK's Key Drugs
ZEVRA DENMARK's core commercial portfolio centers on MIPLYFFA — its most strategically important drugs approved in the last 15 years.
ZEVRA DENMARK's Recent FDA Approvals
New NDA/BLA approvals for ZEVRA DENMARK over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ZEVRA DENMARK's Therapeutic Areas
Disease areas where ZEVRA DENMARK has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ZEVRA DENMARK Pipeline Snapshot
Active clinical trials for ZEVRA DENMARK across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MIPLYFFA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-09-20
- Latest
- 2024-09-20
- Applications
- 1